New approaches to treatment of various cancers based on cytotoxic analogs of LHRH, somatostatin and bombesin

Andrew V Schally, Attila Nagy

Research output: Contribution to journalArticle

118 Citations (Scopus)

Abstract

The development of targeted cytotoxic analogs of hypothalamic peptides for the therapy of various cancers is reviewed and various oncological studies on experimental tumors are summarized. Novel therapeutic modalities for breast, prostate and ovarian cancer consist of the use of targeted cytotoxic analogs of LH-RH containing doxorubicin (DOX) or 2-pyrrolino-DOX. The same radicals have been incorporated into cytotoxic analogs of somatostatin which can be also targeted to receptors for this peptide in prostatic, mammary, ovarian, renal and lung cancers, brain tumors and their metastases. A targeted cytotoxic analog of bombesin containing 2-pyrrolino-DOX has also been synthesized and successfully tried in experimental models of prostate cancer, small cell lung carcinoma and brain tumors. The development of these new classes of peptide analogs should lead to a more effective treatment for various cancers.

Original languageEnglish
Pages (from-to)2305-2320
Number of pages16
JournalLife Sciences
Volume72
Issue number21
DOIs
StatePublished - Apr 11 2003
Externally publishedYes

Fingerprint

Bombesin
Somatostatin
Gonadotropin-Releasing Hormone
Brain Neoplasms
Doxorubicin
Tumors
Prostatic Neoplasms
Ovarian Neoplasms
Brain
Breast Neoplasms
Neoplasms
Peptides
Peptide Receptors
Kidney Neoplasms
Small Cell Lung Carcinoma
Lung Neoplasms
Theoretical Models
Cells
Neoplasm Metastasis
Therapeutics

Keywords

  • Breast cancer therapy
  • Lung cancer therapy
  • Ovarian cancer therapy
  • Prostate cancer therapy
  • Renal cancer therapy
  • Targeted cytotoxic analogs

ASJC Scopus subject areas

  • Pharmacology

Cite this

New approaches to treatment of various cancers based on cytotoxic analogs of LHRH, somatostatin and bombesin. / Schally, Andrew V; Nagy, Attila.

In: Life Sciences, Vol. 72, No. 21, 11.04.2003, p. 2305-2320.

Research output: Contribution to journalArticle

@article{fe44d416683a4e989e67e2ca4d70eb65,
title = "New approaches to treatment of various cancers based on cytotoxic analogs of LHRH, somatostatin and bombesin",
abstract = "The development of targeted cytotoxic analogs of hypothalamic peptides for the therapy of various cancers is reviewed and various oncological studies on experimental tumors are summarized. Novel therapeutic modalities for breast, prostate and ovarian cancer consist of the use of targeted cytotoxic analogs of LH-RH containing doxorubicin (DOX) or 2-pyrrolino-DOX. The same radicals have been incorporated into cytotoxic analogs of somatostatin which can be also targeted to receptors for this peptide in prostatic, mammary, ovarian, renal and lung cancers, brain tumors and their metastases. A targeted cytotoxic analog of bombesin containing 2-pyrrolino-DOX has also been synthesized and successfully tried in experimental models of prostate cancer, small cell lung carcinoma and brain tumors. The development of these new classes of peptide analogs should lead to a more effective treatment for various cancers.",
keywords = "Breast cancer therapy, Lung cancer therapy, Ovarian cancer therapy, Prostate cancer therapy, Renal cancer therapy, Targeted cytotoxic analogs",
author = "Schally, {Andrew V} and Attila Nagy",
year = "2003",
month = "4",
day = "11",
doi = "10.1016/S0024-3205(03)00113-9",
language = "English",
volume = "72",
pages = "2305--2320",
journal = "Life Sciences",
issn = "0024-3205",
publisher = "Elsevier Inc.",
number = "21",

}

TY - JOUR

T1 - New approaches to treatment of various cancers based on cytotoxic analogs of LHRH, somatostatin and bombesin

AU - Schally, Andrew V

AU - Nagy, Attila

PY - 2003/4/11

Y1 - 2003/4/11

N2 - The development of targeted cytotoxic analogs of hypothalamic peptides for the therapy of various cancers is reviewed and various oncological studies on experimental tumors are summarized. Novel therapeutic modalities for breast, prostate and ovarian cancer consist of the use of targeted cytotoxic analogs of LH-RH containing doxorubicin (DOX) or 2-pyrrolino-DOX. The same radicals have been incorporated into cytotoxic analogs of somatostatin which can be also targeted to receptors for this peptide in prostatic, mammary, ovarian, renal and lung cancers, brain tumors and their metastases. A targeted cytotoxic analog of bombesin containing 2-pyrrolino-DOX has also been synthesized and successfully tried in experimental models of prostate cancer, small cell lung carcinoma and brain tumors. The development of these new classes of peptide analogs should lead to a more effective treatment for various cancers.

AB - The development of targeted cytotoxic analogs of hypothalamic peptides for the therapy of various cancers is reviewed and various oncological studies on experimental tumors are summarized. Novel therapeutic modalities for breast, prostate and ovarian cancer consist of the use of targeted cytotoxic analogs of LH-RH containing doxorubicin (DOX) or 2-pyrrolino-DOX. The same radicals have been incorporated into cytotoxic analogs of somatostatin which can be also targeted to receptors for this peptide in prostatic, mammary, ovarian, renal and lung cancers, brain tumors and their metastases. A targeted cytotoxic analog of bombesin containing 2-pyrrolino-DOX has also been synthesized and successfully tried in experimental models of prostate cancer, small cell lung carcinoma and brain tumors. The development of these new classes of peptide analogs should lead to a more effective treatment for various cancers.

KW - Breast cancer therapy

KW - Lung cancer therapy

KW - Ovarian cancer therapy

KW - Prostate cancer therapy

KW - Renal cancer therapy

KW - Targeted cytotoxic analogs

UR - http://www.scopus.com/inward/record.url?scp=0037432496&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037432496&partnerID=8YFLogxK

U2 - 10.1016/S0024-3205(03)00113-9

DO - 10.1016/S0024-3205(03)00113-9

M3 - Article

C2 - 12639697

AN - SCOPUS:0037432496

VL - 72

SP - 2305

EP - 2320

JO - Life Sciences

JF - Life Sciences

SN - 0024-3205

IS - 21

ER -